Heather Wakelee, MD

Articles

Dr. Wakelee on Importance of NGS Testing in NSCLC

March 12th 2019

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses the importance of next-generation sequencing testing in the treatment of patients with non–small cell lung cancer.

Dr. Wakelee on Unmet Needs for Immunotherapy in NSCLC

March 6th 2019

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses unmet needs for immunotherapy in the treatment of patients with non–small cell lung cancer.

Dr. Wakelee Discusses Current State of Treatment in NSCLC

January 27th 2019

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLC

September 8th 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Dr. Wakelee on Single-Agent Immunotherapy in NSCLC

August 2nd 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses single-agent immunotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Wakelee on Recent Advancements in EGFR-Mutant NSCLC

July 28th 2018

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.

Dr. Wakelee on Available Treatments Following Tumor Progression in Lung Cancer

March 27th 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses available treatment for patients with lung cancer who progress without a T790M mutation.

Dr. Wakelee Discusses EGFR TKIs in Lung Cancer

March 21st 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses EGFR tyrosine kinase inhibitors (TKIs) in lung cancer.

Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung Cancer

March 12th 2018

Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.

The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?

January 1st 2018

With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.

Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC

December 7th 2016

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Wakelee on Immunotherapy Versus Targeted Agents in NSCLC

July 20th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Dr. Heather Wakelee on What to Do When Resistance to EGFR TKIs Emerges

March 24th 2016

Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).

Dr. Wakelee on Proteomic Testing in Non-Small Cell Lung Cancer

March 3rd 2015

Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University Medical Center, discusses VeriStrat testing for patients with non-small cell lung cancer.

Dr. Wakelee on Continued Maintenance in Lung Cancer

August 15th 2014

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses continued maintenance therapy in lung cancer.

Dr. Wakelee Discusses the AVAPERL Trial

August 30th 2013

Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, discusses the results of the AVAPERL trial.

Dr. Wakelee on Nintedanib Plus Chemotherapy in NSCLC

August 9th 2013

Heather Wakelee, MD, from the Stanford University School of Medicine, describes two phase III trials that focused on the second-line nintedanib plus chemotherapy to treat patients with advanced non-small cell lung cancer.

Dr. Wakelee on the Future of Lung Cancer Adjuvant Therapy

October 18th 2011

Dr. Heather Wakelee from the Stanford Clinical Cancer Center on the Future of Lung Cancer Adjuvant Therapy

Dr. Wakelee on Using Lymph Nodes for Lung Cancer Staging

October 10th 2011

Dr. Heather Wakelee from Stanford Clinical Cancer Center on Using Lymph Nodes for Lung Cancer Staging

Dr. Wakelee on Adjuvant Therapy Predictive Markers

September 30th 2011

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers